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Abstract
 CYP4F (Cytochrome P4504F) enzymes metabolize endogenous molecules 
including leukotrienes, prostaglandins and arachidonic acid. The involvement of 
these endogenous compounds in inflammation has  led to the hypothesis that 
changes in the inflamed tissue environment may affect the expression of CYP4Fs 
during the pro-inflammatory state, which in turn may modulate inflammatory 
conditions during the anti-inflammatory state. We demonstrated that inflamed 
tissues have different levels of CYP4F isoform expression profiles in a number of 
human samples when compared to the average population. The CYP4F isoform 
expression levels change with the degree of inflammation present in tissue. Further 
investigation in cell culture studies revealed that inflammatory cytokines, in 
particular TNF-!, play a role in regulating the expression of the CYP4F family. One 
of the isoforms, CYP4F11, had different characteristics than that of the other five 
CYP4F family members. CYP4F11 metabolizes xenobiotics while the other 
isoforms metabolize endogenous compounds with higher affinity. CYP4F11 also 
was expressed at high quantities  in the brain, and was up-regulated by TNF-!, 
while the other isoforms were not expressed at high quantities in the brain and 
were down-regulated by TNF-!. We identified the AP-1 protein of the JNK pathway 
as the signaling protein that causes significant increase in CYP4F11 expression. 
v
Since TNF-! stimulation causes a simultaneous activation of both JNK pathway 
and NF-"B signaling, we investigated further the role that NF-"B plays on 
expression of the CYP4F11 gene. We concluded that although there is a significant 
increase in CYP4F11 expression in the presence of TNF-!, the activation of NF-"B 
signaling inhibits CYP4F11 expression in a time dependent manner. The 
expression of CYP4F11 is only significantly increased after 24 hours of treatment 
with TNF-!; at shorter time points NF-"B signaling overpowers  the JNK pathway 
activation. We believe that these findings may in the future lead to improved drug 
design for modulating inflammation.
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Chapter One: Introduction
1
Cytochrome P450 Superfamily
Discovery, Nomenclature, Evolution
 The Cytochrome P450 (CYPs) family of hemoproteins is the largest and 
most functionally diverse superfamilies of enzymes. They are responsible for the 
oxidation, peroxidation, and reductive metabolism of many endogenous 
compounds such as fatty acids, prostaglandins, leukotrienes, steroids and biogenic 
amines. A great number of the CYPs are also able to metabolize xenobiotics 
including drugs, environmental pollutants, natural plant products, and alcohols [1]. 
The ability for mammalian tissues to oxidize non-polar xenobiotics was known in 
the early 1950’s, however the enzyme or enzymes responsible for the catalysis 
were not [2]. In 1958 studies from pig and rat microsomal protein fractions noted 
the existence of a spectral absorbance peak (Soret peak) at 450nm in the 
presence of carbon monoxide [2]; this  was later identified as a P450 hemoprotein 
[3]. This unique spectral absorbance peak is where CYPs obtain their name. 
 Human CYPs are named using the following system: CYP, denoting 
cytochrome P450, an Arabic number designating the P450 family, a letter 
indicating the subfamily when there are two or more subfamilies known, and then 
followed by an Arabic numeral representing the individual gene [1]. For example: 
CYP4F11. If a CYP sequence displays  amino acid identity that is greater than 40% 
they are grouped into the same family [2]. If those sequences are greater than 55% 
identical then they are placed in the same subfamily, followed by a sequence 
identity of 97% or higher resulting in alleles [2].
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 The human genome encodes 57 CYP proteins (http://drnelson.utmem.edu/
CytochromeP450.html). A recent survey performed by the Guengerich group 
classified fifteen CYPs as being involved in the metabolism of xenobiotic 
chemicals, fourteen being involved in the metabolism of sterols; four that oxidize 
fat-soluble vitamins; and nine involved in the metabolism of fatty acids and 
eicosanoids in which for the topic of my dissertation the CYP4F family resides. The 
remaining fifteen CYPs substrates are undesignated [4]. 
 The first CYP is believed to have been present as early as three and a half 
billion years ago [2]. The thought is that as  the earth’s atmosphere accumulated 
more molecular oxygen CYPs were recruited to protect life forms from oxygen 
toxicity. There was then a switch wherein metabolism of toxic plant allelochemicals, 
xenobiotics and, thereby, modern pharmaceuticals arose as an important feature of 
the cytochrome P450 gene superfamily [2]. It is  hypothesized that during evolution 
there was a “plant-animal warfare,” whereby animals  evolved new P450s  to 
synthesize the toxic phytoalexins produced by plants  [5]. It is  this evolution of CYP 
dependent metabolism of plant metabolites by insects and mammals that is  most 
likely linked to present day role of CYPs ability to detoxify pollutants, toxins and 
pharmaceuticals [2].
Monoxygenase system
 Cytochrome P450s main function is to activate molecular oxygen to yield a 
reactive species that can attack chemical sites to form hydroxyl groups into 
structures as unreactive as hydrocarbon chains and aromatic rings [6]. There are 
three major components  to the monoxygenase enzyme system: 1) Heme protein, 
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CYP, 2) the flavoprotein, NADPH CYP-reductase and 3) phospholipids [7]. The 
reductase is needed to transfer two electrons to the CYP thus providing reducing 
equivalents to the heme iron for reduction of molecular oxygen and product 
formation during catalysis [4]. The basic reaction takes one molecular oxygen atom 
and inserts it into a substrate (SH), the second atom being reduced to water:
The CYP catalytic cycle follows steps shown in Figure 1.1 [4]. The main steps are 
as follows: 
1. Substrate binds to CYP recognition site
2. An electron from NADPH via Cytochrome P450 reductase reduces heme 
ferric iron
3. Oxygen binds the ferrous iron
4. Second electron forms the peroxy iron complex
5. Cleavage of the O-O bond forming H2O and a reactive iron-oxo complex
6. Oxygen is then transferred to the bound substrate
7. Product is released
4
NAD(P)H + O2 + SH + H+       NAD(P)+ + SOH + H2O
Figure 1.1 Cyctochrome P450 catalytic cycle. The Cytochrome 
P450 enzymes act as monoxygenase systems, where molecular O2 
is used to oxidize lipophilic substrates (RH). This figure is adapted 
f rom the PROMISE mirror database (websi te: ht tp: / /
metallo.scripps.edu/PROMISE/P450.html)
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Hepatic and extra hepatic metabolism
 Even though there are many different families of CYPs the conventional 
wisdom has been that xenobiotics  are mainly metabolized by the CYP families 
CYP1, CYP2, and CYP3 [8]. With current research in our laboratory we have also 
found that one isoform of the CYP4F family is as good at metabolizing xenobiotics 
as CYP3A4 the CYP responsible for metabolizing about 30% of clinically available 
drugs [7]. In mammals, the liver is the major organ with cytochrome P450 
expression and activity. However, the presence of phase I metabolizing enzymes, 
which include CYPs [9],[10],[11] along with phase II metabolizing enzymes [9], [11], 
and phase III transporters  [12],[13], are also expressed across many other tissues. 
This  distribution of metabolizing enzymes also makes them promising candidates 
for drug delivery. However, most of the studies conducted on phase I CYP 
enzymes are focused mainly on the CYP families 1,2, and 3, and since our 
laboratory has uncovered the ability of CYP4F11 to metabolize drugs, we have 
focused thisP450s research to examine the distribution of the 4F family in the 
human body and how the CYP4Fs are regulated.
Cytochrome P450s as therapeutic targets 
 Currently there are several CYPs that have been targets for drug design, 
chiefly CYP19A1 and CYP5A1. CYP19A1 or aromatase is responsible for a key 
step in the biosynthesis of estrogens, and it is this  function that drug design has 
been utilized to inhibit its  function [14]. Estrogen production is  a component of 
some cancer processes and other diseases and thus the use of this  CYP as  a drug 
target has had a great affect on the treatment of estrogen-related diseases. 
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Furthermore, CYP5A1 or thromboxane A synthase specializes  in converting 
prostaglandin H2 to thromboxane A2, a potent vasoconstrictor and inducer of 
platelet aggregation [15]. Drugs designed as thromboxane A synthase inhibitors 
are valuable as antithrombotic and antihypertensive drugs [16]. For most other 
CYPs the attempts to inhibit their activities to achieve either greater drug 
availability, as  in the case of CYP3A4 substrates, or to inhibit the progression of a 
known function, such as synthesis of arachidonic acid, is  still in the beginning 
stages [7]. Nevertheless, since the goal is to serve people with an effective 
treatment for disease, knowledge of the function, regulation and expression of 
cytochrome P450s as they regulate drug availability and inflammation is important 
in obtaining that goal.
Inflammation and Cytochrome P450s
 Another complication for drug design is the fact that during many diseases 
and infections the normal host defense mechanism is activated and mediators of 
inflammation are present throughout the body. This is  a problem because 
inflammation modifies the expression, activity, and functions of drug-metabolizing 
enzymes and drug transporters [17]. Mainly, the inflammatory stimuli cause 
decreased catalytic abilities of CYPs which could lead to the dose-dependent drug 
toxicity associated with impaired drug clearance [18]. Thus, understanding the role 
inflammation plays in regulating CYPs is very important for clinical drug therapy in 
disease states. During an inflammatory response the liver’s  ability to handle drugs 
is  not optimal and the expression of CYP genes are down-regulated at the 
transcript levels [18], which leads  to the observed decreased catalytic abilities. 
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Carcillo et al. showed that children with sepsis had a twofold reduction in antipyrine 
clearance compared to controls [19]. This study shows the importance of 
inflammatory mediator regulation of a number of CYPs and how marker 
inflammatory mediators may play a role. In their study they focused on the cytokine 
Interleukin-6 (IL-6) and nitric oxide (NO) [19]. They concluded that for drugs 
metabolized by CYPs there needs to be a reevaluation of the use of standard drug 
dosage schedules especially for patients with sepsis, which show a high increase 
in host defense inflammation measures [19]. Figure 1.2 is  a pathway proposed for 
the loss of catalytic activity during an inflammatory response [20]. 
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Figure 1.2. Modified proposed pathway for the loss in drug 
metabolism during an inflammatory response. Diseases cause 
an inflammatory response that causes the release of cytokines from 
macrophages, and monocytes which lead to a modified 
transcription profile of genes that are active in the liver. These 
changes down-regulate most of the CYP genes expressed in the 
liver. Which ultimately lead to a low drug clearance and high 
chance of drug toxicity [20].
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 An important nuclear transcription factor in the mediation of inflammation is  
the nuclear transcription factor-kappa B (NF-!B). Two classic cytokines can lead to 
the release of  NF-!B, interleukin-1# (IL-1#) and tumor necrosis factor-alpha (TNF-
"); stimulation of NF-!B by these two cytokines is considered the classical pathway 
[21]. This current research project focuses mainly on these cytokines because of 
their up-regulation during normal host defense processes, and their down stream 
activation of NF-!B, which also serves as an important transcription factor in the 
regulation of CYPs. NF-!B regulates over 200 genes involved in a plethora of 
cellular processes [22],[23],[24],[25]. NF-!B is composed of hetero- or homo-
dimers of five members, p52, p50, p65 (RelA), RelB, and c-Rel and each unit has 
its own biological activity [21]. NF-!B has been reported to mechanistically regulate 
the transcription of CYPs either by indirectly regulating the gene through mutual 
repression between NF-!B and many other nuclear receptors, or by directly 
binding to the response element of the CYP gene [22]. Another mechanism that 
has also been reported is the ability of NF-!B to affect the stability of the CYP on 
the protein level [26], [22]. The mechanistic capabilities of NF-!B and its  ability to 
regulate CYPs are important in the scheme of understanding the expression 
response of CYPs during an inflammatory response so that drug design and 
patient care can be improved. 
 Most current studies examining changes observed in CYP expression 
during normal host defense mechanism response have been performed on CYP 
Families  1,2 and 3 [20],[27],[19]. Our laboratory is working on the effects that 
inflammatory mediators and thus host response mediators have on the CYP4F 
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family and the significance of this information for the future of drug design and 
resolution of inflammation.
Cytochrome P450 4F subfamily
Function
 The Cytochrome P450 4F (CYP4F) family was first discovered by two 
different groups as part of an effort to define an inactivation pathway for leukotriene 
B4 (LTB4), a powerful mediator of inflammation [28],[29]. The CYP4Fs catalyze $ 
and $-1-hydroxylation reactions; it is this reaction that aids in the removal of LTB4, 
(Figure 1.3) a prominent proinflammatory signal which, when left unregulated, can 
cause secondary harmful effects [30]. 
 There are seven CYP4F isoforms presently known to be expressed in 
humans: CYP4F2, CYP4F3A, CYP4F3B, CYP4F8, CYP4F11, CYP4F12 and 
CYP4F22. Table 1.1 shows each family members’ characteristics. It is important to 
note that of the seven isoforms the primary drug metabolizer is CYP4F11 [31]. 
However, it is the ability of most of the family members to metabolize multiple 
mediators  of inflammation and regulatory processes such as LTB4, prostaglandins 
and arachidonic acid (AA) that has  been the focus of the current project on the 
regulation of these important enzymes.
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Figure 1.3 Enzymatic pathway for metabolism of 
LTB4[32]. After Leukotriene B4 is produced CYP4Fs are 
able to start the deactivation process  of LTB4 by 
hydroxylation.
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Table 1.1 CYP4F subfamily members and their respective 
known substrates
14
Expression and Distribution
 There have been a few reports about the location of many different CYP4Fs 
throughout the human body. CYP4F2 was shown to be expressed in liver, kidney, 
skin and several other tissues and tumors  [32],[33]. CYP4F3 was shown to be 
expressed in the human liver, while CYP4F8 was shown to be present in seminal 
vesicles, epidermis, hair follicles, sweat glands, proximal renal tubules, and 
epithelial linings of the gut and urinary tract [34]. CYP4F11 has been localized to 
the human liver, kidney, heart, brain and skeletal muscle [35]. Lastly, CYP4F12 has 
been reported to be expressed in the liver, kidney, seminal vesicles, small 
intestine, prostate gland and ovarian follicles [36],[37],[38]. While the presence of 
these isoforms have been identified in a great variety of human tissues, there has 
not been a complete analysis of the expression level of each isoform of the family 
as a comparison study to see which isoforms are the predominant members of the 
family in each tissue. This  information would help in understanding the role that the 
family has in the human body. 
Regulation of CYP4Fs during inflammation
 Inflammation is  known for its  contribution to the host defense mechanism 
where it aids  in the fight against infection by a variety of pathogens as well as 
tissue injury. On the other hand, it also can become diffuse and uncontrolled and 
thereby produce unwanted complications. The importance of CYP4Fs are shown 
during this process because after a bacterial infection or tissue injury 
polymorphonuclear leukocytes (PMNL) or neutrophils are activated and recruited 
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to the site of inflammation by mediators such as LTB4 that causes chemotaxis to 
the site of injury [39],[40]. The CYP4Fs ability to control the inactivation of LTB4 
plays an important role in making sure excess LTB4 is  not in the system, which 
could lead to unregulated inflammation. Studies  examined the changes in CYP4F 
expression during an inflammatory response to determine if indeed the CYP4Fs 
have a capability to resolve inflammation [41]. Kalsotra et al. hypothesized that 
during the pro inflammatory phase of host defense there was a low expression 
level of CYP4Fs, which begins to show a marked up-regulation of CYP4Fs as the 
anti-inflammatory phase starts. This  elevation of CYP4F activity supports the 
resolution of the excess of inflammatory mediators [32]. These findings have led 
our laboratory to study the functions of the specific CYP4F isoforms that are 
expressed in the human, and examine how they are regulated during an 
inflammatory response. Our goal is  to provide a basis  for how these important 
enzymes work throughout an inflammatory episode. This understanding may in the 
future lead to better drug design for modulating inflammation.
16
Chapter Two: Human Distribution, Expression and 
Inflammatory Mediator Regulation of CYP4Fs
17
Abstract
 Cytochrome P450s (CYP) play a central role in the the metabolism, 
elimination and detoxification of xenobiotics but many of them play a key role in the 
metabolism of endogenous compounds. The CYP4F family is instrumental in the 
inactivation of leukotriene B4, a potent inflammatory mediator. However, not much 
is  known about the relative expression of each CYP4F isoform in human tissues. In 
this  study we determined the expression profiles of the CYP4F isoforms in the liver, 
lung, heart, kidney and spleen. We show that during an inflammatory response in 
tissue samples the profile of the CYP4F isoforms change and that the changes 
seen are consistent with the presence of inflammatory cytokines. Using the HepG2 
human liver cell line we determined that IL-1#, TNF! and IL-6 causes a decrease 
in CYP4F expression, but that IL-1# and TNF! causes an increase in CYP4F11 
expression, which is a different regulatory response from its other family members. 
Overall, the study confirms what was shown in animal model studies is also seen 
in human tissues and cells.
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Background
 Cytochrome P450s (CYP) catalyze lipophilic compounds into compounds 
that are more soluble. They play a central role in the metabolism, elimination and 
detoxification of xenobiotics. Studies have recently focused on the extra-hepatic 
metabolic capacities of these enzymes and shown discrete and different activity 
profiles for extra hepatic tissues. There is also evidence that the different tissue 
organs regulate extra-hepatic drug metabolizing enzymes in a specific manner that 
may be associated with the function of that tissue [9]. Several studies have been 
performed in animal models to determine the distribution and expression of 
cytochrome P450s [42][43]. However, it is not always possible to translate animal 
distribution studies to humans with accuracy and certainty [44]. This  lack of close 
correlation may be due to the differences in the number of cytochromes P450 and 
isoform specificity from one species to another [45].
 Our current study focuses on the CYP4F family of enzymes and their 
localization and regulation. This CYP4F family was first identified because of the 
ability to inactivate leukotriene B4 (LTB4), a powerful mediator of inflammation [28]. 
Currently seven identified human isoforms in the CYP4F family have been 
identified, and in this study we focus on CYP4F2, CYP4F3A, CYP4F3B, CYP4F11 
and CYP4F12. These isoforms vary in their substrate specificity. CYP4F2 is  known 
for its ability to metabolize LTB4 or arachidonic acid (AA) [46]. CYP4F3A and 
CYP4F3B are splice variants of each other that are able to metabolize LTB4 and 
AA [47]. Christmas et al. were able to show that CYP4F3A has a greater ability of 
metabolizing and deactivating LTB4 [47] while CYP4F3B is  more efficient at 
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metabolizing AA into 20-hydroxyeicosatetraenoic (20-HETE) [48]. CYP4F11, unlike 
the other members of the CYP4F family, is efficient at catalyzing xenobiotics with 
higher affinity than endogenous compounds  like LTB4 and AA [31]. The final 
isoform in this study is CYP4F12; it is  able to metabolize AA and prostaglandins 
(PG), which may also help in the termination of inflammation [36]. 
 To determine the distribution of CYP4F isoforms in human liver, lung, 
spleen, heart and kidney, we designed qRT-PCR assays that quantify the mRNA of 
each of the CYP4F isoform family members. We also examined the role 
inflammatory mediators play in the expression and regulation of the CYP4F 
isoforms under in vivo and in vitro conditions. 
Materials and Methods
Chemicals
 IL-1#, TNF! and IL-6 were obtained from Invitrogen Inc. (Carlsbad, CA). 
Human Sample RNA
 Pooled Human RNA were purchased from Clontech, Mountain View, CA. 
Human tissue samples from the liver, heart, lung, spleen and kidney were also 
collected and flash frozen by the Department of Pathology at the University of 
Texas Health Science Center Houston from Memorial Hermann Hospital. This was 
done in accordance to IRB approval by the University of Texas  Health Science 
Center Houston. A description of the human samples is presented in Table 2.1. 
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Cell Culture
 HepG2 cell line was obtained from the American Type Culture Collection 
(Manassas, VA). Cells were grown at 37oC in a humidified incubator with 5% CO2 
in Minimum Essential Medium (Sigma-Aldrich) supplemented with 10% fetal bovine 
serum (Atlas Biologicals, Fort Collins, CO), L-glutamine and Pen/strep antibiotics. 
Cytokine treatments were administered 24 hours after seeding the cells and the 
cells were treated for 24 hours in each case unless otherwise noted.
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
 Human samples were homogenized in TRIzol reagent (Invitrogen) while 
cells were rinsed with phosphate-buffered saline (PBS), and then subjected to 
RNA isolation using TRIzol reagent (Invitrogen). DNase I (Invitrogen) was  used to 
alleviate DNA contamination. Aliquots (100 ng) of total RNA were reverse-
transcribed by SuperScript II Reverse Transcriptase (Invitrogen) in triplicate, 
including a reverse transcription blank to evaluate the presence of contaminating 
genomic DNA. Amplification was performed using Taq DNA Polymerase 
(Invitrogen) with an ABI Prism 7700 (Applied Biosystems, Foster City, CA) at 95oC 
for 1min, followed by 40 cycles at 95oC for 12s and 60oC for 30s. CYP4F mRNA 
levels  were measured using standard curves generated by plotting Ct versus the 
log of the amount of purified amplicon for CYP4F (custom synthesis by Invitrogen) 
(200ag - 2pg). Abundance of human 18S RNA was used as an internal control. 
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Table 2.1. Total RNA Source Information
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Sample     Tissue Type     Sex    Pool Size          Age    Race      C.O.D.
Clontech! Li! ! M!    1! ! 51!    C! Sudden Death
Clontech! Lu! ! M/F!    3! ! 32-61!    C! Sudden Death
Clontech! K! ! F!    1! ! 40!    C! Sudden Death
Clontech! S! ! M/F!    12! ! 18-54!    C! Sudden Death
Clontech! H! ! M!    3! ! 30-39!    C! Trauma
H673! ! Li,Lu,K,S,H! F!    1! ! 71!    C! CRF, HTN
H678! ! Li,Lu,K,S,H! M!    1! ! 50!    C! Li/K Failure
H693! ! Li,Lu,K,S,H! M!    1! ! 58!    C! Septic Shock
H696! ! Li,Lu,K,S,H! F!    1! ! 78!    C! Septic Shock
H6103! ! Li,Lu,K,S,H! F!    1! ! 63!    C! Septic Shock
Li=Liver, Lu=Lung, K=Kidney, S=Spleen, H=Heart, M=Male, F=Female, C=Caucasian, 
AA=African American,CRF=Cardiorespiratory Failure, HTN=Hypertension
Primers and fluorescent probe sequences for CYP4F isoforms and 18S RNA are 
reported in Table 2.2.
Statistical Analysis
 Data are presented as mean ± S.E.M. One-way analysis of variance 
followed by Dunnett’s multiple comparison test was used for the statistical analysis. 
Statistical differences were considered significant if P <0.05.
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Table 2.2. Sequences of oligonucleotides comprising Human 
CYP4F isoform TaqMan assays
Name!            Primers/Probes    !       5ʼ-3ʼ Sequence
CYP4F2     ! Forward Primer! CCAGAACAGGCCAATCTGAA
! ! Reverse Primer! CTCCTCAGTCCCACCTCCC
! ! Probe! ! ! ATGCATAGCGGATTGGTGGCTTTCA
CYP4F3A! Forward Primer! TCTGGATGGGCCCCATCT
! ! Reverse Primer! TTGATGACAGACCGGATGATGT
! ! Probe! ! ! CGTCATCCGTTTTTGCCACCC
CYP4F3B ! Forward Primer! GCCCTGGCACGCAATC
! ! Reverse Primer! GGAGCAAAGAGCACAGGCTT
! ! Probe! ! ! TCCGCATCTTCCACCCCACCTAC
CYP4F11! Forward Primer! CGAAACAGAACTGGTTTTGGG
! ! Reverse Primer! GGTCAATGTCTTCATGCCCTC
! ! Probe! ! ! AGGGCCTGGTCACTCCCACGG
CYP4F12! Forward Primer! ATGTCGGCCACCTATTCCC
! ! Reverse Primer! AGGGTGGCATAAAACGATGA
! ! Probe! ! ! TTACGGTATGGCTGGGTCCCATCAT
Human 18S! Forward Primer! GAGGGAGCCTGAGAAACGG
! ! Reverse Primer! GTCGGGAGTGGGTAATTTGC
! ! Probe! ! ! TACCACATCCAAGGCAGCAGG
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Results
CYP4F Isoform expression is varied across human tissue samples
 Our laboratory has previously shown that in the rat the expression of CYP4F 
isoforms are varied across liver, lung, brain and kidney rat tissues [49]. We 
designed this current study to determine the expression profile of the various 
CYP4F isoforms across human liver, lung, heart, kidney, spleen and brain tissue.
Liver 
 The CYP4F2 isoform was the predominant CYP4Fs being expressed in the 
human liver with the other isoforms showing minimal expression. The CYP4F 
isoform expression level ranking is  CYP4F2 > CYP4F3B > CYP4F11 > CYP4F12 > 
CYP4F3A as is represented in Figure 2.1.
Lung
 In the human lung the CYP4F isoform distribution was as follows: 
CYP4F3B> CYP4F12 > CYP4F11 > CYP4F2 > CYP4F3A. CYP4F3B represented 
a significant large percentage of the CYP4F expression in the human lung, while 
CYP4F3A had only minimal expression levels. Figure 2.1.
Heart
 In the heart the distribution of CYP4Fs follows the order of CYP4F3B > 
CYP4F12 > CYP4F2 > CYP4F11 ~ CYP4F3A as seen in Figure 2.1
Spleen
 The spleen had the following order of expression: CYP4F3B > CYP4F2 > 
CYP4F12 > CYP4F11 ~ CYP4F3A. The expression in the spleen shows a 
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representation of mostly CYP4F3B with a smaller expression profile for CYP4F2. 
There is minimal expression of CYP4F3A, CYP4F11 and CYP4F12.
Kidney
 The kidney like the liver was very high in expression of CYP4F2 and 
CYP4F3B isoforms. The distribution is  as follows: CYP4F2 > CYP4F3B > 
CYP4F11 ~ CYP4F12 > CYP4F3A.
 The distribution of CYP4F isoforms in various tissues are represented in the 
pie chart showing their relative expression (Figure 2.2). This varying degrees of 
isoform distribution is consistent with the differences in expression levels observed 
in our previous studies of the rat model [49]. 
Patient samples with diseases that have an inflammatory component have 
varied level of CYP4F expression
 To determine whether inflammation plays a role in the regulation of CYP4Fs 
we examined patient samples with an inflammatory component implicated in the 
cause of death. The cause of death was determined by a pathologist using 
markers of inflammation in histological slides of each tissue. We were able to 
compare the degree of alteration in CYP4F expression profile occurring in each 
tissue in comparison to the averaged expression levels for each form in each 
tissue. Figure 2.3A shows a representative sample of a patient with a disease with 
an inflammatory component and illustrates the changes in the expression profile of 
CYP4Fs resulting from inflammation in that tissue. The liver sample from patient 
H6103 liver had inflammatory markers based on histological markers seen in the 
slide Figure 2.3B. Increased inflammatory markers are identified as an infiltration of 
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neutrophils  and leukocytes. As noted in Table 2.1 the cause of death for patient 
H6103 was septic shock, which causes the release of a myriad of inflammatory 
mediators  throughout the body. Further, pathological analysis of the liver resulted 
in an inflammatory rating of two and a diagnosis of hepatitis. When examining the 
distribution differences between liver sample H6103 and pooled liver we found 
significant increase in expression of CYP4F11, CYP4F3B, and CYP4F3A isoforms. 
Figure 2.4A also shows a representative sample of a patient with a disease that 
included an inflammatory component and the alterations it causes in the 
expression profile of CYP4Fs. The liver sample from patient H696 liver had 
increased inflammatory markers such as infiltrated neutrophils and leukocytes, as 
is  seen in Figure 2.4B. As noted in Table 2.1 patient H696 died of septic shock as 
well, and the spleen was given an inflammatory rating of two with a reactive 
hyperplasia and the presence of hemorrhage and white pulps. When examining 
the distribution differences between sample H696 and pooled liver we observed 
significant increase in CYP4F11, CYP4F2, and CYP4F3A isoform expression. 
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Figure 2.1. Transcript Copy Numbers of CYP4F Isoforms Across 
Different Tissues. Total RNA from samples listed in Table 2.1 were 
used to asses  the mRNA transcript numbers of CYP4F isoforms in 
the liver, lung, heart, kidney and spleen. CYP4F2 and CYP4F3B 
shows the highest level of transcript copies across most tissues. 
CYP4F3A, CYP4F11 have minimal expression across varied tissues 
and CYP4F12 showed differences from high in the lung to low out of 
most other tissues. 
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Figure 2.2 Isoform and Tissue Specific CYP4F Distributions.
Total RNA from samples listed in Table 2.1 were prepared and 
assayed using qRT-PCR as described in the Methods and Materials 
section. The pie charts represent the relative distribution of CYP4F 
isoforms in the liver, lung, kidney, heart and spleen.
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Figure 2.3. Sample 103 Inflamed Liver Compared to Pooled 
Liver.
A) Sample 103 inflamed liver that was diagnosed with hepatitis was 
used to compare any changes seen in CYP4F isoforms in a 
diagnosed inflammatory tissue. There was an increase in CYP4F11, 
CYP4F3A, and CYP4F3B while there was a reduction in CYP4F2 
expression. B) A representative histological slide of sample 103’s 
liver with an increase of infiltrated neutrophils  which represents the 
presence of inflammation.
32
33
Figure 2.4. Sample 96 Inflamed Spleen Compared to Pooled 
Spleen.
A) Sample 96s’ inflamed spleen that was diagnosed with reactive 
hyperplasia was used to compare any changes seen in CYP4F 
isoforms in a diagnosed inflammatory tissue. There was an increase 
in CYP4F11, CYP4F3A, and CYP4F2 while there was a reduction in 
CYP4F3B expression. B) A representative histological slide of sample 
96s’ spleen with an increase of infiltrated neutrophils which 
represents the presence of inflammation.
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Specific cytokines can change CYP4F isoform expression in HepG2 cells
 To determine whether if proinflammatory cytokines can regulate the 
changes seen in CYP4F isoforms we conducted a 24-hour treatment study on 
HepG2 cells  with cytokines and measured the levels mRNA transcripts of each 
CYP4F isoform. We tested IL-1#, TNF! and IL-6 cytokines  and found that in most 
cases IL-1# and TNF! caused a down regulation of CYP4F isoforms (CYP4F2, 
CYP4F3B, and CYP4F12) while IL-6 seemed to play little to no role in regulating 
the CYP4Fs. CYP4F11 however showed an increase in transcript levels in the 
presence of both IL-1# and TNF!. The ability to change CYP4F expression profiles 
in a controlled environment provides more evidence that indeed the inflammatory 
response in human tissues induce changes  to these enzymes that metabolize 
xenobiotics endogenous compounds.
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Figure 2.5. Cytokine Regulation of CYP4F Isoforms in HepG2 
cells.
HepG2 cells were plated then treated for 24 hours  with either Vehicle, 
IL-1#, TNF! or IL-6 (10ng/ml). Total RNA was collected after the 24 
hour time-period and qRT-PCR was used to quantify the specific 
isoform expression amount. IL-1# and TNF! were able to change the 
expression profiles of CYP4F2, CYP4F3B, CYP4F12 and CYP4F11. 
IL-6 did not vary much from control levels.
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Discussion
 Phase I metabolizing enzyme research has focused on the liver as the 
preferred site of experiments because of its known role as the principle organ of 
biotransformation [50]. It is also believed that xenobiotics are mainly metabolized 
by cytochrome P450 (CYP)1,2 and 3 family members, and that the other family 
members focus mainly on endogenous compound trasformation [8]. There has 
been extensive work done on the regulation, expression profile and function of 
these family members [43][51-53]. Though much research has  focused on the liver 
because of its functional role in biotransformation, every major tissue has some 
ability to metabolize xenobiotics [50]. Knowing this  information is  important 
because when considering drug disposition the total effect must determined; thus 
the additive effect of all tissues is important [54]. Many studies have examined the 
expression and localization of members  of the CYP family of genes. Five members 
of the CYP2C family have been examined by Tsao et al. and they found that there 
were varied expression profiles of the genes across the murine model [55]. They 
determined that the sites of these enzymes’ expression also play a functional role 
in that specific tissue [55]. Ding et al. published a review that examined the CYP1, 
2 and 3 families to identify their presence in different parts of the respiratory and 
gastrointestinal tracts [56]. Another study determining the expression and 
localization of the CYP3A subfamily found that the genes were expressed at 
different levels across different tissues and suggested that this was due to tissue 
specific regulation of the promoter region [57]. There is a limited amount of 
information about the distribution and localization of the CYP4F family in humans. 
39
We undertook to examine the liver, lung, heart, kidney and spleen of a variety of 
human samples  and determine the averaged mRNA expression of the CYP4F 
isoforms using the highly sensitive technique qRT-PCR. We found that CYP4F2 
and CYP4F3B were the most expressed CYP4F isoforms across the different 
human tissues. CYP4F2, which is responsible for the inactivation of LTB4 and 
metabolizes AA into 20-HETE, was highly expressed in the liver and the kidney. Jin 
et al., reported that the Chinese Human Liver Proteome Profiling Consortium had 
obtained 42% CYP4F2 and 29% CYP4F3 relative protein abundance in the liver as 
compared with CYP3A4 [58]. This finding is consistent with the mRNA levels  that 
we have seen in the liver, and they are in the correct order of relative abundance. It 
is  also important to note that the high levels of CYP4F2 and CYP4F3B in the 
kidney can produce 20-HETE that helps modulate vascular tone and renal tubular 
function [59, 60]. CYP4F3A was the original CYP4F3 found in neutrophils  and is 
known for its ability to inactivate LTB4, and CYP4F3B was found to be highly 
present in liver and kidney using northern blot techniques [48]. We also found that 
there was  a high level of CYP4F12 transcripts in the heart and lung, and very little 
in the other tissues. It has been reported that CYP4F12 protein is  expressed in the 
liver and kidney in small amounts, but that the highest expression of CYP4F12 
protein was in the seminal vesicles and prostate gland [38]. They reported little to 
no CYP4F12 protein in the aorta and no information was reported about the lung 
[38]. Thus, further studies would have to be performed to see precise localization 
of the CYP4F12 protein to determine whether the mRNA expression levels 
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correlate with protein levels. Overall, CYP4F11 showed small amounts  of 
expression across all the tissues tested.
 This  study determined the constitutive levels of Human CYP4F isoforms so 
that there could be a comparison of what these levels are during an inflammatory 
response. Many studies have reported that inflammatory mediators can cause a 
change in the expression profile of CYPs [20, 27, 61-63]. The idea that the same 
down-regulation that occurs in other CYPs could effect the CYP4F family is  mainly 
based on animal model studies done in our lab and other laboratories  that show 
that after injury and the pro-inflammatory stage there is  a down-regulation of 
CYP4Fs. This  down-regulation is then reversed in the pro-inflammatory stage of 
healing where there is an increase in CYP4Fs to help in resolving the inflammatory 
mediators  such as LTB4 [64-67]. To study this we compared known inflamed 
tissues defined by histological analysis from patient samples and compared them 
to our pooled tissue samples. We found that there is a change in CYP4F 
expression profile in the presence of inflammatory mediators. Of importance is the 
higher expression of CYP4F3A seen in these samples, which we believe is 
correlative to the presence of neutrophils at the site of injury/inflammation. 
However, the changes seen in the CYP4Fs maybe based on a number of signaling 
processes that need to be studied in a different system, which is why we went to 
cell culture to identify signaling pathways  for changes we saw in the CYP4F 
expression.
 During an inflammatory response or injury a number of cytokines are 
released as part of the host response [68]. We chose to determine how IL-1#, 
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TNF! and IL-6 would effect the expression of the CYP4Fs. We found that for a 
majority of the CYP4Fs, IL-1# and TNF! treatment caused down-regulation of 
mRNA CYP4F transcripts except for that of CYP4F11. IL-6, however, seems to 
have little to no effect on the expression of the CYP4Fs. We also found that there 
was no significant difference between cytokine-treated and control CYP4F3A 
expression. The conclusion that CYP4F11 can be up-regulated during an 
inflammatory response and its ability to metabolize xenobiotics could potentially be 
beneficial to pharmaceutical companies looking for a way to control unwanted 
inflammatory mediators in tissues. Understanding more about the regulatory 
controls of the CYP4F family and their ability to resolve inflammation, although still 
in its infancy stage, could become a major help in treating patients.
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Chapter Three: Isoform, Ethnicity and Sex Specific 
Expression Differences in Human Orbital Frontal 
Cortex
43
Abstract
! Cytochrome P450s play an important role in the brain. They are responsible 
for metabolism of neurosteroids, neurotransmitters,and xenobiotics in the brain. 
This study  determined the expression of the isoforms of CYP4F family  of enzyme 
in the orbital frontal cortex. We found that CYP4F11, an enzyme that metabolizes 
xenobiotic and endogenous compounds was expressed at a significantly higher 
quantity than its other family members. Immuno-histochemical studies revealed 
that the CYP4F11 protein is localized in neuron and glial cells and that expression 
of CYP4F11 is not ubiquitous across all cells. We also found that while gender 
does not affect the CYP4F isoform expression in the orbital frontal cortex, ethnicity 
does. African Americans express CYP4F11 at a significantly higher rate than their 
Caucasian counterparts. Overall, this study is the first demonstration of the 
importance of CYP4F11 expression in brain.
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Background
! Extensive work has been done on the metabolism of xenobiotics in the liver 
and extra-hepatic tissues. This is because xenobiotics are found in all facets of our 
environment, they range from the drugs we take to the air we breath to the food we 
eat. Cytochrome P450s (CYP) have been identified as the key enzyme that starts 
the detoxification process for these compounds by transforming them from 
lipophilic to more polar hydrophilic metabolites. Because xenobiotics come in a 
variety of shapes and sizes, the CYP enzymes have been located in all tissues and 
consist of a diverse number of enzymes within its superfamily. Although there has 
been extensive research on the CYP expression in the liver and other extra-
hepatic tissues the brain has special properties that make it unique. One of the 
main characteristics that is unique to the brain is the presence of the blood brain 
barrier (BBB). The BBB is made up  of 3 cellular components: endothelial cells, 
astrocyte feet and pericytes [69]. The BBB is further characterized by the presence 
of tight junctions which help  create a selective barrier to prevent the transport of 
hydrophilic molecules across the BBB; however, small lipophilic compounds and 
molecules can cross the barrier [69]. The astrocyte end feet that cover 90% of the 
endothelial cell surface can also release chemical factors and signals that can 
regulate the permeability of the endothelium [70]. The brainʼs limited ability  to 
regenerate and the lipophilic characteristics of xenobiotics leaves the brain 
vulnerable to damage by toxic compounds. Thus the presence of CYPs to 
metabolize any  lipophilic compound that enters the brain is of great importance in 
detoxification and therefore protection of the brain. 
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! Many of the CYP family members have been identified in the brain, and they 
include CYP subfamilies 1, 2, 3 and 4 [71]. What many researchers have found is 
that the expression levels of CYPs in the brain are about 1-10% of that in the liver 
[72, 73]. Although there is less representation of CYPs in the brain, the expression 
of most are in specific regions of the brain, and some members of the CYP family 
of enzymes also show specific splice variants in the brain. 
! Although CYPs play a role in catalyzing the detoxification of xenobiotics 
crossing the BBB, a greater majority of CYPs in the brain specialize in the 
formation of biologically important lipid signaling molecules such as eicosanoids 
and steroid hormones. These molecules include: estrogen, corticosteroids, bile 
acids, vitamin D, and androgens [74]. Another important function of CYPs in the 
brain is the synthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) from 
aracidonic acid (AA). This activity is important because 20-HETE plays a role in 
regulating cerebral blood flow and helps in the vasodilation actions of nitric oxide in 
cerebral circulation [75]. Studying CYP4F expression in the brain is of great 
importance because of this last point. Many of the isoforms in the CYP4F family 
metabolize AA into 20-HETE and to know their expression patterns in the brain 
helps us understand more about how the brain is functioning. This current study 
was planned to identify which CYP4F isoforms are expressed in the brain and 
identify cell types, whether it be neuronal or glial, that express the CYP4Fs. 
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Materials and Methods
Human Sample RNA
 Brain samples  were collected from the National Institutes of Health by Dr. 
Thomas Hyde in accordance to NIH IRB approval of human samples. All samples 
were from the orbital frontal cortex, and sample descriptions are listed in Table 3.1. 
Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
 Human samples were homogenized in TRIzol reagent (Invitrogen) while 
cells were rinsed with phosphate-buffered saline (PBS), then subject to RNA 
isolation using TRIzol reagent (Invitrogen). DNase I (Invitrogen) was used to 
alleviate DNA contamination. Aliquots (100 ng) of total RNA were reverse-
transcribed with SuperScript II Reverse Transcriptase (Invitrogen) in triplicate, 
including a reverse transcription blank to evaluate presence of contaminating 
genomic DNA. Amplification was performed using Taq DNA Polymerase 
(Invitrogen) with an ABI Prism 7700 (Applied Biosystems, Foster City, CA) at 95oC 
for 1min, followed by 40 cycles at 95oC for 12s and 60oC for 30s. CYP4F mRNA 
levels  were measured using standard curves generated by plotting Ct versus the 
log of the amount of purified amplicon for CYP4F (custom synthesis by Invitrogen) 
(200ag - 2pg). Abundance of human 18S RNA was used as an internal control. 
Primers and fluorescent probe sequences for CYP4F isoforms and 18S RNA are 
reported in Table 3.2.
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Sample BrainRegion AGE (yr) Gender Ethnicity PMI (hr)
910
922
942
1007
1051
1053
1054
1056
1099
1109
1127
1275
1276
1314
1443
1458
1473
1522
1525
Orbital Frontal Cortex 52 F AfAm 10
Orbital Frontal Cortex 51 M Cauc 30.5
Orbital Frontal Cortex 61 M Cauc 19.5
Orbital Frontal Cortex 57 M AfAm 25
Orbital Frontal Cortex 57 F AfAm 19
Orbital Frontal Cortex 40 F AfAm 25
Orbital Frontal Cortex 58 M AfAm 28.5
Orbital Frontal Cortex 48 M AfAm 37
Orbital Frontal Cortex 67 F AfAm 34
Orbital Frontal Cortex 59 F Cauc 23
Orbital Frontal Cortex 43 F AfAm 72
Orbital Frontal Cortex 60 M AfAm 13
Orbital Frontal Cortex 24 M AfAm 43.5
Orbital Frontal Cortex 53 F AfAm 50.5
Orbital Frontal Cortex 56 M Cauc 29.5
Orbital Frontal Cortex 34 M Cauc 13.5
Orbital Frontal Cortex 44 M AfAm 29
Orbital Frontal Cortex 64 F AfAm 52.5
Orbital Frontal Cortex 46 M AfAm 13
Table 3.1. Total Brain RNA Characteristic Information
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F=Female, M=Male, AfAm=African American, Cauc=Caucasian, PMI=Post-Mortem Interval
Table 3.2. Sequences of oligonucleotides comprising Human 
CYP4F isoform TaqMan assays
Name!            Primers/Probes    !       5ʼ-3ʼ Sequence
CYP4F2     ! Forward Primer! CCAGAACAGGCCAATCTGAA
! ! Reverse Primer! CTCCTCAGTCCCACCTCCC
! ! Probe! ! ! ATGCATAGCGGATTGGTGGCTTTCA
CYP4F3A! Forward Primer! TCTGGATGGGCCCCATCT
! ! Reverse Primer! TTGATGACAGACCGGATGATGT
! ! Probe! ! ! CGTCATCCGTTTTTGCCACCC
CYP4F3B ! Forward Primer! GCCCTGGCACGCAATC
! ! Reverse Primer! GGAGCAAAGAGCACAGGCTT
! ! Probe! ! ! TCCGCATCTTCCACCCCACCTAC
CYP4F11! Forward Primer! CGAAACAGAACTGGTTTTGGG
! ! Reverse Primer! GGTCAATGTCTTCATGCCCTC
! ! Probe! ! ! AGGGCCTGGTCACTCCCACGG
CYP4F12! Forward Primer! ATGTCGGCCACCTATTCCC
! ! Reverse Primer! AGGGTGGCATAAAACGATGA
! ! Probe! ! ! TTACGGTATGGCTGGGTCCCATCAT
Human 18S! Forward Primer! GAGGGAGCCTGAGAAACGG
! ! Reverse Primer! GTCGGGAGTGGGTAATTTGC
! ! Probe! ! ! TACCACATCCAAGGCAGCAGG
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Immunohistochemical Analysis
! Tissue fixation and immunohistochemistry solvents were all certified 
histological grade and obtained from Fisher Scientific (Pittsburgh, PA). Brain 
samples were fixed in 10% formalin solution, after surgical extraction by our 
neuropathologist colleague from Memorial Herman Hospital. Samples were then 
fixed being dehydrated in a series of ethanol (50%, 70%, 95%, 100%) and xylene 
solutions (100%), then embedded in paraffin wax. The wax block molds of brain 
tissue were then sectioned and mounted onto poly-L-lysine coated glass slides. 
For immunohistochemical analysis, the slides were rehydrated and then taken 
through an antigen retrieval process. The tissue samples were incubated at 4oC 
overnight in primary antibody solution, then incubated for at least 1 hour in 
secondary antibody solution. The primary antibody solution contained antibody to 
CYP4F11 (1:100) and antibody to either MAP2 (1:500), or GFAP (1:1000). The 
secondary antibody solution was either AlexaFluor-594 anti-rabbit (1:250) or 
AlexaFluor-488 anti-mouse (1:250). The slides were also treated with ProLong 
Gold Antifade Reagent that contained DAPI to stain for cell nuclei. The slides were 
then visualized on a fluorescence microscope and images were captured using 
SPOT RT Slider imaging system. The background color of the microscope images 
was adjusted using Adobe Photoshop.
Statistical Analysis
 Data are presented as mean ± S.E.M. One-way analysis of variance 
followed by Dunnett’s multiple comparison test was used for the statistical analysis. 
Statistical differences were considered significant if P <0.05.
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Results
Cytochrome P450 4F11 is expressed highly in the Orbital Frontal Cortex.
! To understand the expression levels of the CYP4Fs in the orbital frontal 
cortex of the human brain we performed qRT-PCR using specific primer and probe 
sets that distinguish between each isoform in the CYP4F family. 100ng of RNA 
from each sample was analyzed and plotted in Figure 3.1. We found that CYP4F11 
is the most highly expressed CYP4F isoform in the orbital frontal cortex. There was 
little to no expression of CYP4F2 and CYP4F3B in the brain samples. CYP4F3A 
was the next most abundant isoform expressed followed by CYP4F12. 
Numerically, CYP4F11 represented 88% of the CYP4F family presence in the 
orbital frontal cortex and had 20000-25000 transcripts per 100ng of RNA. The 
order of relative abundance is described as CYP4F11 > CYP4F3A > CYP4F12 > 
CYP4F3B ~ CYP4F2 
Gender does not affect CYP4F expression in brain
! Studies have shown that gender can be a factor in the expression of CYP 
enzymes [76, 77]. To elucidate whether gender plays a role in CYP4F expression 
in brain, the data obtained from male (n=11) and female (n=8) samples was 
compared and demonstrated that gender does not play a significant role in the 
expression of CYP4Fs in the orbital frontal cortex (Figure 3.2).
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Figure 3.1. CYP4F Isoform Transcript Copy Numbers In Human 
Brain. A) Total RNA from samples listed in Table 3.1 were used to 
asses the mRNA transcript numbers of CYP4F isoforms in the brain. 
B) CYP4F11 shows the highest level of transcript copies compared to 
other CYP4F’s.
52
Figure 3.2 Gender differences of CYP4F expression are not 
observed In orbital frontal cortex.
qRT-PCR was used to obtain transcript copy numbers for each 
CYP4F isoform and compared between male and female samples to 
determine if gender has an affect on CYP4F expression in the brain. 
We determined that there were no significant gender differences 
seen in any CYP4F isoform’s expression in the brain.
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CYP4F11 expression is more abundant in African Americans compared to 
Caucasians
! There is growing evidence that ethnicity  may play a role in the expression of 
CYP enzymes [78-81]. To determine if ethnicity  was a factor in the expression of 
the CYP4F family of enzymes we analyzed the expression of each isoform in the 
orbital frontal cortex of each of our samples. We then compared the African 
American samples (n=14) to the Caucasian samples (n=5) for each isoform and 
determined differences if any in the expression of the enzyme (Figure 3.3). We 
found that CYP4F11 is expressed in high quantities in the African American 
population as compared to the Caucasian population. CYP4F2 on the other hand 
showed a greater presence in the Caucasian population as compared to the 
African American population where the expression of CYP4F2 was either low or 
absent in the sample population. However, due to the variance in the Caucasian 
population this finding was not significant at the P<0.05 level. This trend was also 
seen in the expression of CYP4F3B and CYP4F12. CYP4F3A, however, showed 
few differences in expression between the two ethnic populations.
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Figure 3.3 Ethnicity Differences of CYP4F Isoforms In Human 
Brain.
qRT-PCR transcript copy number comparison between African 
American and Caucasian samples to determine if ethnicity has an 
affect on CYP4F expression in the brain. CYP4F11 expression in 
African Americans is  significantly higher than in their Caucasian 
counterparts. CYP4F2, CYP4F3B and CYP4F12 showed higher 
expression in Caucasian samples, but it was  not statistically 
significant at the P<0.05 level. There also was no difference in 
CYP4F3A expression between the two ethnicities.
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Cytochrome P450 4F11 is expressed selectively in both glial and neuronal 
cells
! Immunofluorescent techniques were used to determine the expression of 
the protein in human brain samples. We used microtubule-associated protein 2 
(MAP-2) to stain for neuronal cells, and glial fibrillary acidic protein (GFAP) to stain 
for glial cells, specifically astrocytes, in the brain (Figure 3.4 and Figure 3.5). 
CYP4F11 is being expressed in both glial and neuronal cells, but in specific cell 
types of each. The merged picture shows the overlap of CYP4F11 and either 
MAP-2 or GFAP. It also appears that the CYP4F11 is not present in the nuclei of 
these cells.
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Figure 3.4. Localization of CYP4F11 Protein In Human Brain Glial 
Cells. 
A) Immuno-fluorescent slide of human brain, DAPI staining of nuclei. 
B) GFAP (1:1000) in green staining glial cells C) CYP4F11 (1:100) in 
red. D) Merged picture showing overlap of GFAP and CYP4F11. 
There are also areas of no overlap representing CYP4F11 being 
expressed in other cells
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Figure 3.5. Localization of CYP4F11 Protein In Human Brain. 
A) Immuno-fluorescent slide of human brain. CYP4F11 (1:100) in red 
and GFAP (1:1000) in green with DAPI staining of nuclei. Highlighted 
area shows that there is overlap of CYP4F11 and Glial Cells B) 
CYP4F11 (1:100) in red and MAP2 (1:1000) in green with DAPI 
staining of nuclei. Highlighted area shows that there is  overlap of 
CYP4F11 and Neurons.
A.
B.
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Discussion
! Currently  many cytochrome identification studies in the brain have shown 
the expression of the Cytochrome P450 families 1,2 and 3 in the brain [82-84]. 
However, recently  there have been significant strides in identifying CYP4F 
expression in the brains of animals. These papers have focused on the importance 
of the endogenous compound metabolism and the pathways by which CYP4F 
metabolites may have on regulatory functions. There have been a few studies that 
identify human CYP4Fs in brain, but none that have taken a comprehensive look at 
the human CYP4F family expression [85-87].  In the current study we were able to 
show that the expression of CYP4Fs in the human orbital frontal cortex is 
dominated by  CYP4F11. This finding is surprising because many CYP4Fs that are 
expressed in small quantities in the brain are expressed in large quantities in other 
tissues, as shown in Chapter 2 of this dissertation. However, what was not 
surprising was finding expression of CYP4F11. CYP4F11 was first identified and 
cloned from brain tissue and identified in other tissues as well, so its presence was 
expected [35]. The presence of a strong CYP4F11 expression provides further 
evidence that the brain may have evolved to express specific isoforms to perform 
multiple tasks. Kalsotra et al., reported that CYP4F11 was able to metabolize a 
great variety of pharmaceutical drugs including erythromycin, benzphetamine, 
imipramine and verapamil with acceptable turn-over rates [88]. However, the 
authors also show that although the turn-over rate for endogenous compounds 
such as leukotriene B4 (LTB4) is not as high as those of other CYP4F isoform 
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family members, CYP4F11 is still able to metabolize this compound and others 
such as the conversion of arachidonic acid (AA) to 20-HETE [88].
! The presence of high CYP4F11 mRNA concentration in brain led us to 
investigate the localization of CYP4F11 protein in the brain. We found that 
CYP4F11 protein is located in both neuronal and glial cells. Since CYP4F11 is able 
to metabolize both endogenous compounds like AA and xenobiotics such as drugs, 
we believe this dual cell type expression is beneficial for the brain functions of 
signaling and detoxification. A majority of CYP enzymes have been reported to 
localize to neuronal cells [89, 90]. The localization of CYP4F11 in neuronal cells 
could prove to be important because the site of action for psychoactive drugs is in 
the neurons [91].
! When determining the expression levels of each CYP4F isoform we found 
little to no expression of CYP4F2 and CYP4F3B in the brain, and as mentioned 
earlier in this dissertation these two enzymes metabolize AA into 20-HETE. As 
mentioned in the introduction of this chapter, 20-HETE is important in the 
neurovascular system of the brain and production of this compound would have to 
happen in the cells closest to the site of blood flow, such as the glial cells. The 
presence of CYP4F11 in the glial cells and the virtual absence of expression of 
CYP4F3B and CYP4F2 suggests a prominent physiological role for CYP4F11 in 
brain may be the conversion of AA into 20-HETE. Metea et al., were able to show 
that when the CYP4F ω-hydroxylation of AA is inhibited with HET0016 in glial cells, 
vasoconstriction is blocked [92].
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! We found that the expression of CYP4F11 protein may not be present in all 
neuronal and glial cells. Dutheil et al., recently published a review which reported 
when CYPs are expressed in the brain they are usually  seen in specific cell types 
and are not ubiquitously expressed throughout brain regions [71]. Further research 
needs to be conducted with samples from a larger set of brain regions to define 
specific markers for the many different types of neuronal and glial cells in the brain.
! This current study also shows that gender plays no obvious role in the 
expression of CYP4F isoforms in the orbital frontal cortex. There have been many 
reports that provide evidence that gender can affect the expression of CYPs. 
Waxman et al., recently published a review of CYP families 1,2 and 3 showing how 
sex differences cause changes in expression of the CYPs [77]. In the future, with 
additional brain regions and larger sample sizes, a significant differences in 
expression between genders may emerge, but our study did not find any.
! We did find that ethnicity-based differences in expression does occur 
between African Americans and Caucasians. Our data shows that African 
Americans express CYP4F11 at a significantly higher rate than Caucasians. The 
Ravindranath laboratory  also found that in the Indian population CYP4F11 was 
expressed at a much higher level compared to the other CYP4F family members 
(personal communication). A large number of our sample group consisted of 
African American samples, so the addition of more Caucasian samples would help 
in identifying whether CYP4F11 can be expressed in a high quantity  in this group. 
We examined the promoter region of CYP4F11 for single nucleotide 
polymorphisms (SNPs) Figure 3.6. Using HapMap (www.hapmap.org), we found 
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that a SNP labeled rs3810427(C/A) occurs at a rate of .868/.132 in African 
Americans while it is .496/.504 for most Caucasians while the other SNPs in Figure 
3.6 were equal in both ethnicities. This means that the C  nucleotide occurs 87% of 
the time in African Americans while in Caucasians this occurrence is only 50%. The 
SNP in this region could be in a critical promoter region binding site, or there also 
could be other SNPs in the gene that could be causing the difference in 
expression. This work is a preliminary attempt to understand the differences 
between the two ethnicities in CYP4F11 expression. Additional work is needed in 
this area to more fully understand any differences in expression. Other studies 
have also determined that ethnic differences play a role in the expression and 
function of many CYPs. Yamaori et al., for instance, reported that there was a 
difference in expression of CYP3A5 between Japanese and Caucasian subjects 
[81]. 
! Our CYP4F expression work in human brain is a beginning for additional 
studies of CYP4Fs in the brain. As more work is done to identify  the expression, 
localization and functional capabilities of CYPs in the brain is accomplished, there 
is a higher probability of identifying potential brain drug target opportunities and 
perhaps useful therapies.
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Figure 3.6. 1.7kb 5ʻUTR of CYP4F11. The promoter region is 
marked with annotation of SNPs that occur in the population. SNPs 
were located using HapMap, www.hapmap.org. and sequence was 
analyzed using Geneious (BioMatters)
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Chapter Four: Regulation of Cytochrome P450 
4F11 by Nuclear Transcription Factor-Kappa B
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Abstract
 The mechanisms that regulate CYP4F genes are currently being studied in 
a number of laboratories, but the specific mechanisms for the regulation of these 
genes are not yet fully understood. This study shows that nuclear factor kappa-
light-chain-enhancer of activated B cells  (NF-"B) can inhibit CYP4F11 expression 
in human liver carcinoma cell line (HepG2). Tumor necrosis  factor-! (TNF-!), a 
proinflammatory cytokine has been shown to activate NF-"B signaling while also 
making active the c-Jun N-terminal Kinases (JNK) signaling pathway. Previous 
studies have reported that JNK signaling can up-regulate CYP4F11 expression, 
and in this study we have determined that in the presence of TNF-! and the 
specific NF-"B translocation inhibitor IMD-0354 there is a greater increase in 
CYP4F11 expression, indicating that NF-"B may be playing an inhibitory role. 
Furthermore, NF-"B stimulation by over-expression of Mitogen-activated protein/
ERK Kinase Kinase (MEKK) inhibited CYP4F11 promoter expression. We were 
also able to  rescue CYP4F11 promoter inhibition in the presence of TNF-! when 
p65, a NF-"B protein, was knocked down. Thus, the CYP4F11 gene is  negatively 
regulated by NF-"B signaling pathways. 
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Background
 
 The release of several cytokines including tumor necrosis factor (TNF)-!, 
interleukin (IL)-1, IL-1b, and IL-6 from activated immune cells in patients with a 
disease with an inflammatory component, or infection occur as part of the 
activation of systemic host defense mechanisms. This  defense mechanism and the 
release of these cytokines  usually results in the down-regulation of many isoforms 
of cytochrome P450 (CYP) [93-98]. This is important due to the known 
responsibilities of the CYP systems in the metabolism of drugs used in treatment of 
such conditions  as well as steroids, lipid soluble vitamins, prostaglandins, 
leukotrienes. If there is a disruption in the balance of these enzymes to metabolize 
their substrates  there could be an alteration in the production or elimination of 
these substances and an interruption in the balance between the detoxification and 
metabolic bioactivation in the body.
 One of the prominent cytokines, TNF-!, is  known to be released during 
many types of infections and inflammatory diseases [95], and in our current study 
we used this cytokine to define the effects its presence has  on the regulation of 
cytochrome P450 4F11, an isoform of the 4F family that has a substrate profile that 
includes not only endogenous compounds but also xenobiotics specifically drugs
[88]. TNF-! stimulation causes an activation of two signal transduction pathways 
the c-Jun N-terminal Kinases (JNK) and nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-"B) pathways [99-101]. Our previous studies have 
examined the role JNK and retinoic acids play in the regulation of CYP4F11 and 
have found that JNK stimulation causes an increase in CYP4F11 mRNA while 
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retinoids cause down-regulation of CYP4F11 mRNA [102]. However, we did not 
examine the effects of NF-"B on CYP4F11 expression during TNF-! stimulation.
 To understand at a deeper level the regulation of CYP4F11 expression 
during inflammation we show in this  study that TNF-! and MEKK over-expression 
can down-regulate CYP4F11 expression in NF-"B dependent manner. Our results 
suggest that there is an intricate regulatory system for control of expression of 
CYP4F11 during conditions wherein inflammatory modulators are released.
Materials and Methods
Chemicals
 N-[3,5-Bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (IMD-0354) 
was obtained from Sigma-Aldrich (St. Louis, MO). TNF! was a gift from Dr. 
Jianping Jin (University of Texas-Houston). IL-1 were bought from Invitrogen Inc. 
(Carlsbad, CA). Polyclonal anti-CYP4F11 antibody was provided by Proteintech 
Group, Inc. (Chicago, IL). Rel B and p65 antibodies were bought from Cell 
Signaling (Danvers, MA).
Cell Culture
 HepG2 cell line was obtained from American Type Culture Collection 
(Manassas, VA). Cells were grown at 37oC in a humidified incubator with 5% CO2 
in Minimum Essential Medium (Sigma-Aldrich) supplemented with 10% fetal bovine 
serum (Atlas Biologicals, Fort Collins, CO), L-glutamine and Pen/strep antibiotics.
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Protein Isolation and Western Blot Analyses
 Protein isolation and western blot analyses for cells in culture were 
accomplished using the protocol reported by Wang et al., 2010 [102]. Briefly, Cells 
were washed two times with ice cold phosphate-buffered saline and then quickly 
detached by gently scraping the plate. Collected cells were spun down at 4500rpm 
for 2min at 4oC, in a microcentrifudge and stored at -80oC. Lysates were then 
prepared using 50mM Tris-HCl buffer, pH6.8, with 2% SDS. Cell pellets  were 
dissolved in the lysate buffer then boiled at 95oC for 5 minutes. The cell lysate was 
then cleared by centrifugation at 13,000 rpm for 5 minutes in a microcentrifudge. 
Protein concentrations  of the clear supernatant fraction were measured using the 
bicinchoninic acid assay kit (Pierece, Rockford, IL) and subjected to Western blot 
analysis.
 Protein samples were boiled in Laemmli buffer and resolved 
electrophoretically on 4 - 20% gradient Tris-glycine-SDS-polyacrylamide gels  (Bio-
Rad Laboratories, Hercules, CA). Proteins were transferred to polyvinylidene 
fluoride membranes (wet transfer apparatus; Bio-Rad Laboratories). Membranes 
were blocked with 5% dried non-fat milk in Tris Buffer with .05% Tween for 1 hour. 
Membranes were incubated overnight with antibodies raised against CYP4F11 
(1:1000 dilution), Rel B (1:1000), p65 (1:1000), or GAPDH (1:10,000). The 
membrane was then washed and incubated at room temperature with horseradish 
peroxidase-conjugated secondary antibody (1:2000 dilution) for 1 hour. 
Immunoreact iv ty was v isual ized us ing a horseradish perox idase 
chemiluminescense system (Pierce).
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Quantitative Real-Time Polymerase Chain Reaction
 Cells  were rinsed with phosphate-buffered saline (PBS), and total RNA was 
isolated using TRIzol reagent (Invitrogen). DNase I (Invitrogen) was used to 
alleviate DNA contamination. Aliquots (100 ng) of total RNA were reverse-
transcribed by SuperScript II Reverse Transcriptase (Invitrogen) in triplicate, 
including a reverse transcription blank to evaluate presence of contaminating 
genomic DNA. Amplification was performed using Taq DNA Polymerase 
(Invitrogen) with an ABI Prism 7700 (Applied Biosystems, Foster City, CA) at 95oC 
for 1min, followed by 40 cycles at 95oC for 12s and 60oC for 30s. CYP4F11 mRNA 
levels  were measured using standard curves generated by plotting Ct versus the 
log of the amount of purified amplicon for CYP4F11 (custom synthesis by 
Invitrogen) (200ag - 2pg). Abundance of human 18S RNA was used as  an internal 
control. Primers and fluorescent probe sequences for CYP4F11 and 18S RNA are 
reported in Table 4.1.
Plasmids
 pGL3-CYP4F11 plasmid mutants were constructed using human genomic 
DNA as a template for PCR. The primer pairs for each mutant are listed in Table 
5.2. The products  were all 3’ promoter regions of the CYP4F11 (GenBank 
accession no. NG_0008335). The PCR products were then cloned into HindIII- and 
NheI- digested linear pGL3 Basic lucifearse vector (Promega, Madison, WI) using 
the infusion Advantage PCR Cloning Kit (Clontech, Mountain View, CA).
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Transfection and Luciferase Assays
 Cells  were transfected using Fugene HD Reagent (Roche, Indianapolis, IN) 
according to the manufacturer’s protocol. Cells  were seeded onto 24 well plates  (5 
x 104 cells/well). 24 hours after seeding, cells were transfected at a recommended 
Reagent:DNA ratio of 4.5:1 with 0.5 µg DNA/well including .03 µg of phRL-SV40 
(Promega). Total amount of DNA was maintained at a constant concentration by 
adding empty pcDNA3 vector when appropriate. After 24 h of transfection, TNF-! 
(10 ng/ml) or IMD-0354 (1 ng/ml) treatment was given for 24 h.
RNAi
 Double-stranded, siRNAs targeting p65 were designed and synthesized by 
S igma-A ldr ich (S t . Lou is , MO) 5 ‘GACAUUGAGGUGUAUUUCA3’ , 
5‘UGAAAUACACCUCAAUGUC3’, and reverse transfected into HepG2 cells using 
Lipofectamine RNAiMAX (Invitrogen). In short, 24 well plates  were seeded (5 x 104 
cells/well) in the presence of 6 (pmol) and 1µl of Lipofectamine RNAiMAX in 100µl 
of Opti-Mem I Serum (Invitrogen). Total media volume was 600µl for a final RNAi 
duplex concentration of 10 nM.
Chromatin immunoprecipitation (ChIP) analysis
 Binding of p65 transcription factor to the human CYP4F11 promoter region 
was determined by ChIP assay according to manufacturer’s  protocol (Active Motif, 
Carlsbad, CA). HepG2 cells after either 1 or 24 h treatment with TNF-! (10ng/ml) 
were fixed using 1% formaldehyde in modified Eagle’s  medium for 10 min at 37oC. 
The cells were then washed 1x in cold PBS, then treated with 125 mM glycine to 
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terminate the cross-linking reaction. The cells were washed again with ice cold 
PBS, and collected in PBS containing 1mM phenylmethylsulfonyl fluoride and 
Protease Inhibitor Cocktail (Active Motif, Carlsbad, CA). The cells were lysed and 
sonicated to shear chromatin. 15 µg of chromatin was then incubated overnight at 
4oC with antibody directed against p65. PCR was used to amplify the 222bp region 
upstream of the start site of CYP4F11 from the purified DNA-protein immune 
complexes. PCR products were run on 2% agarose gel and visualized after 
ethidum bromide staining. Controls for the assay were performed using IgG and 
input template DNA. 
Statistical Analysis
 Data are presented as mean ± S.E.M. One-way analysis of variance 
followed by Dunnett’s multiple comparison test was used for the statistical analysis. 
Statistical differences were considered significant if P <0.05.
Database Sequence Analysis
 The TRANSFAC database (BIOBASE, Beverly, MA) was searched using 
AliBaba 2.1 (BIOBASE) for putative NF"-B binding sites  on the 5’ flanking 
sequence (2000 base pairs from the ATG start codon) of CYP4F11 gene.
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Results
NF-!B inhibition increases expression of CYP4F11
 Our lab recently published that CYP4F11 expression is increased upon 
stimulation with TNF-! in Keratinocyte HaCaT cells  [102]. TNF-! activates two 
pathways, one being the JNK pathway which we have reported can up-regulate 
CYP4F11 through AP-1 binding site, and the NF-"B signaling pathway. It was our 
intention to understand what role this transcription factor played in regulation of 
CYP4F11. We first determined that 24-hour treatment of TNF-! (10ng/ml) caused 
an up-regulation of CYP4F11 mRNA in HepG2 cells measured by quantitative real-
time polymerase chain reaction (qRT-PCR). To understand the role NF-"B may 
have on the expression of CYP4F11, we inhibited the ability of NF-"B to 
translocate to the nucleus from the cytoplasm using the chemical inhibitor 
IMD-0354 (1ng/ml). HepG2 cells were co-treated with both the inhibitor and TNF-! 
(10ng/ml) (Figure 4.1). There was a significant increase in the expression of 
CYP4F11 transcripts as compared to control vehicle. Realizing that NF-"B played 
a role in CYP4F11 expression after observing an up-regulation of the gene when 
translocation of NF-"B to the nucleus was inhibited, we looked 2000bp upstream of 
the start site of the gene in TRANSFAC database using the program AliBaba 2.1 
for predictions of transcription factor binding sites (Figure 4.2). The website 
predicted 5 different NF-"B binding sites in the promoter region of CYP4F11. 
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Figure 4.1. NF-!B inhibition increases expression of 
CYP4F11. Up-regulation of CYP4F11 transcripts by 
inhibition of NF-"B. HepG2 cells were treated with 
10ng/ml of TNF + or - IMD-0354 (1ng/ml) NF-"B 
inhibitor for 24 hours. Cells treated with 0.1% DMSO 
were used as the vehicle control. Expression of 
CYP4F11 was quantitated by qRT-PCR. Each data 
point represents n=6
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CYP4F11 promoter activity is downregulated after HepG2 activation by TNF-" 
and MEKK overexpression.
 To determine the TNF-! regulatory region in the CYP4F11 promoter, we 
cloned the 1.7kb region upstream of CYP4F11 exon-2 transcription initiation site 
into pGL3 basic luciferase vector. We first determined the basal promoter activity, 
then activity after treatment with TNF-! and MEKK overexpression in HepG2 cells. 
As seen in Figure 4.3A, MEKK and TNF-! treatment of the transfected cells 
resulted in a 70-75% reduction in CYP4F11 promoter activity. TNF-! and MEKK 
treatment up-regulated control NF-"B luciferase reporter vector activity (Figure 
4.3B) but had no effect on pGL3 basic luciferase control vectors Figure 5.C. This 
suggests that even though TNF-! causes an overall up-regulation of CYP4F11 
transcripts as  seen previously in Figure 4.1, the promoter inhibition is 
accomplished through NF-"B activation. These data are confirmed through the 
over-expression of MEKK which causes a constitutively active NF-"B protein that 
also down-regulates CYP4F11 promoter activity. 
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Figure 4.3. TNF-" and MEKK suppresses CYP4F11 
promoter activity. HepG2 cells were transfected with 
1.7kb CYP4F11 promoter-pGL3 basic luciferase (A) or 
NF-"B luciferase (B) or pGL3-basic luciferase (C) 
reporter vector. 24 hours  post-transfection, the cells 
were treated with TNF-! (10 ng/ml) for 24 hours and 
luciferase activity was measured. Measuring Renilla 
luciferase activity of co-transfected phRL-SV40 
normalized the transfection efficiencies.
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NF-!B responsive region is present in the first 200bp of CYP4F11 promoter
 The prediction of five NF-"B binding sites by AliBaba 2.1 enabled us to 
create three deletion mutants to determine the functional importance of these 
predicted binding sites (Figure 4.4A) Each construct deletes a predicted NF-"B 
binding site. The last 1.5kb mutant construct deleted 3 predicted NF-"B binding 
sites that were within 100bp of each other. HepG2 cells  were transiently 
transfected with all the 5’ deletion constructs with or without MEKK expression 
plasmid and treated with or without TNF-!. All the 5’-deletion constructs of the 
CYP4F11 promoter were down regulated by TNF-! and MEKK except the 1.5kb bp 
CYP4F11 promoter (Figure 4.4B). This result suggests that the NF-"B responsive 
region should be within the first 200bp of CYP4F11 promoter. A chromatin 
immunopercipitation assay was run on the first 222bp of CYP4F11 promoter region 
to see whether the p65 transcription factor was binding to the promoter region to 
cause an inhibition of the promoter. Figure 4.5 shows that the protein does bind to 
the region, and the relative amount of protein binding the region is  TNF-! activation 
time-dependent. The time-dependency of activation of NF-"B and JNK have been 
reported by many labs [101, 103].
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Figure 4.4. NF-!B responsive region present in the first 200bp of 
CYP4F11 promoter. (A) Deletion constructs of CYP4F11 promoter 
(B) HepG2 cells were transiently co-transfected with 4 different 5’-
deletion constructs of CYP4F11 promoter luciferase reporter with or 
without MEKK-pcDNA3 and phRL-SV40 to normalize the transfection 
efficiencies. TNF-! (10 ng/ml) treatment was  initiated 24 hours post-
transfection for 24 hours. Luciferase activity was measured 48 hours 
after transfection.
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Figure 4.5. NF-!B binds to first 200bp region of CYP4F11 
promoter. ChIP assays performed in HepG2 cells that had been 
treated with TNF-! (10 ng/ml) or vehicle control for 1 hour and 24 
hours. The pull down of p65 is seen in the 200bp amplicon region in 
both 1 and 24 hours. 
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NF-!B is required for CYP4F11 down-regulation
 The next goal was to determine the importance of NF-"B in the down-
regulation of CYP4F11 in response to TNF-!. We achieved this  by using the IKK! 
phosphorylation inhibitor IMD-0354. This drug inhibits the translocation of NF-"B to 
the nucleus, thus preventing any regulatory controls NF-"B exerts on its  response 
genes. HepG2 cells were transiently transfected with each CYP4F11 deletion 
luciferase promoter construct, then co-treated with TNF-! (10 ng/ml and IMD-0354 
(1 ng/ml). As shown in Figure 4.6, CYP4F11 promoter activity is not down-
regulated by TNF-! in the presence of IMD-0354. To make sure there were no drug 
interactions that were affecting the results, the experiment was repeated in HepG2 
cells in the presence of siRNA that knocks down p65 thus preventing expression. 
Figure 4.7 shows that after p65 knockdown and in the presence of TNF-! or over-
expression of MEKK down-regulation of CYP4F11 does not occur. These data 
clearly suggest that CYP4F11 down-regulation requires p65 or NF-"B.
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Figure 4.6. IMD-0354 inhibition of NF-!B releases inhibition of 
CYP4F11 transcripts. HepG2 cells were transiently transfected with 
CYP4F11 deletion promoter constructs 24 hours after being plated. 
Cells  were then co-treated with TNF-! and IMD-0354 (NF-"B 
translocation inhibitor) 24 hours post transfection for 24 hours and 
then luciferase activity was measured. Measuring Renilla luciferase 
activity of co-transfected phRL-SV40 normalized the transfection 
efficiencies.
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Figure 4.7. TNF-" and MEKK mediated down-regulation of 
CYP4F11 promoter is NF-!B dependent: HepG2 cells were reverse 
transfected with siRNA against p65 with lipofectamine RNAiMAX. 24 
hours post transfection, HepG2 cells were transiently transfected with 
CYP4F11 luciferase deletion promoter constructs. Cells  were then 
treated with TNF-! 24 hours post luciferase transfection for 24 hours 
and then luciferase activity was measured. Measuring Renilla 
luciferase activity of co-transfected phRL-SV40 normalized the 
transfection efficiencies.
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Discussion
 The ability for cytokines, prostaglandins  and other inflammatory mediators 
to alter the expression of many different CYPs has been the subject of many 
different studies [61, 97, 104, 105]. The importance of this work stems from the 
effects that changes in CYP levels have on the metabolism of many drugs, on the 
homeostasis of steroid hormones and on the ability of CYPs to detoxify 
xenobiotics. The effects of inflammation on CYP expression are varied, but the 
predominant effect is that inflammatory cytokines suppress  the gene expression of 
most CYPs. In the current study we have presented a novel regulatory role for 
CYP4F11 expression during an inflammatory response. We have shown that 
activation of the NF-"B pathway by TNF-! stimulation or over-expression of MEKK 
causes down-regulation of CYP4F11 transcripts. However, what makes this unique 
is  that the inhibition of native CYP4F11 is  not seen in the presence of TNF-! after 
24 hours (Figure 4.1) as was seen in this study and in a previous study [102]. We 
believe this is  due to the signal transduction properties  of TNF-!. It is believed that 
the c-Jun N-terminal Kinases (JNK) pathway and the NF-"B pathways are both 
stimulated in the presence of TNF-!; however, they are competing forces [106]. 
The up-regulation of CYP4F11 mRNA in the presence of TNF-! is due to the 
stimulation of the JNK pathway [102], however this  is  time dependent and does not 
reach a level of significance until 24 hours  after treatment as observed in our 
laboratory. This was confirmed in the ChIP analysis where at 1 hour there was a 
large increase in p65 bound CYP4F11 transcripts  that remained constant at 24 
hours.
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 The inhibition seen in CYP4F11 promoter constructs  is driven mainly by NF-
"B activation. We were able to show this  in various experiments including inhibiting 
translocation of NF-"B to the nucleus and then treating HepG2 cells  with TNF-! 
(Figure 4.1). This resulted in a large increase of transcripts leading us  to believe 
that although JNK is a strong stimulator of CYP4F11 expression, NF-"B may be 
playing an inhibitory role. After determining that NF-"B inhibition caused a 
decrease in promoter activity in our constructs (Figure 4.4) we then utilized 
chemical inhibition (Figure 4.6) and protein knockdown (Figure 4.7) of NF-"B and 
determined the effects on the promoter activity. We found that in those cases there 
was either control level expression or over-expression of CYP4F11 gene. This led 
us to believe that the down-regulation of CYP4F11 is NF-"B dependent. The cases 
of over-expression can be explained by the activation of the areas in the promoter 
region that have AP-1 binding sites which would create higher levels  of expression 
of CYP4F11 in the presence of JNK activation. This mechanism was described in a 
recent paper published by our lab in Drug Metabolism and Disposition 2010 [102]. 
In short, JNK activation causes activation of AP-1 protein which regulates 
expression through the AP1 binding site on a gene’s promoter. In the 1.7kb 
CYP4F11 promoter construct there are five AP-1 binding sites positioned 
throughout the promoter region and when TNF-! is  present JNK signaling can still 
occur and elicit regulation of the CYP4F11 promoter construct. Overall, this finding 
is  just one piece of a very complicated mix of regulatory networks that lead to the 
regulation of CYP4F11, and with each finding the pieces of the puzzle are 
beginning to fit. This is pictorially represented in Figure 4.8. Overall, we believe 
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that this  regulation of CYP4F11 may be an important mechanism of compensation 
in cells. As  most CYPs are down regulated during the inflammatory response it is 
unique that CYP4F11 is  up-regulated. CYP4F11 has the ability to compensate for 
the metabolism profiles of CYP4F2 and CYP4F3A/B as  these enzymes are down-
regulated during an inflammatory response. However this  theory needs to be 
tested further with functional studies that can show the effects of inflammatory 
response on activity. This, in addition to regulatory sites found for CYP4F11, may 
help investigators develop drug therapies to one or several regulatory sites to 
modulate pathological inflammation.
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Figure 4.8. Summary of TNF-" Regulation of CYP4F11 
Expression. Diagram of regulation of CYP4F11 expression. TNF-! 
activates pathways for JNK and NF-"B, these two pathways 
although both activated are able to regulate genes that oppose 
each other. What we have found is  that the longer TNF-! is present 
and activating its  receptor the more the JNK pathway is activated, 
this  activation up-regulates CYP4F11 expression, however other 
signaling that can activate NF-"B would cause an inhibition of 
CYP4F11.
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Chapter Five: Conclusions, Significance and 
Future Directions
92
Localization of CYP4Fs
! Although work on the Cytochrome P450 4F family began in the 1990ʼs 
there, is still more work that needs to be done to understand fully  all the 
characteristics of this family. This current work in identifying the mRNA level of 
expression of the CYP4F family in different human tissues is novel in itself and is 
an important step  in translating what we have learned in the animal models to 
human studies. While localizing and determining the relative quantities of the 
CYP4Fs in the liver, lung, spleen, kidney, heart and brain are very important, 
finding that these enzyme profiles change in the presence of inflammatory 
mediators helps in understanding regulation of these enzymes. This is important 
because it is the first time its been shown that human patient samples change 
CYP4F expression levels in a disease state. It also demonstrates the importance 
of animal model testing, where studies have shown that injury causes significant 
changes in the CYP4F expression profile.
! It is important to next examine the protein levels of each isoform in these 
tissues. This has currently been a problem because of 1) the high homology 
between the CYP4F family  which leads to 2) lack of specific antibodies for each 
isoform. This approach will show how the mRNA expression level relates to the 
protein functional expression in tissues. Another approach that should be pursued 
is identifying a specific inflammatory disease and obtain tissue samples from those 
patients in order to compare them to a specified control to determine the exact 
effects a known inflammatory disease model has on CYP4F expression and what 
functionality gain or loss is associated with it.
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CYP4F11 expression in the brain
! This research project identified the expression profile of the CYP4F family in 
the brain, and found hat CYP4F11 was expressed at high quantities. Knowing that 
CYP4F11 has a diverse substance specificity that ranges from xenobiotics to 
endogenous compounds, makes this finding even more relevant and important. It 
is important to note that the orbital frontal cortex is responsible for integrating 
emotion with behavior and is the site of a large number of neurotransmitter 
signaling processes. With the knowledge that 1) CYP4F11 is expressed at high 
levels in this region and 2) that the expression is present in both the neurons, site 
of neurotransmitter action, and glial cells, site or neuroinflammatory control, there 
is the possibility that the enzyme may be a potential drug target for different mental 
disease states affecting this region of the brain. 
! Future work studies should include additional brain regions. This study 
focused on the orbital frontal cortex, but the addition of other regions is needed 
because of the specificity that is seen in other CYPs expressed in the brain. 
Functional studies of CYP4F11 in the frontal cortex would also be beneficial to 
determine how this enzyme can function as a drug target.
NF-κB inhibits CYP4F11 expression
! Work in our laboratory has focused on the regulation of the CYP4Fs during 
an inflammatory response. We have focused on this because of the role CYP4Fs 
play in decreasing inflammatory mediators such as leukotrienes and 
prostaglandins. This current study determined that CYP4F11 is negatively 
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regulated by  the activation of NF-κB. The importance of this finding is that while 
other research has shown that CYP4F11 is up-regulated by TNF-α stimulation this 
current research determined that if NF-κB is blocked and cells are stimulated by 
TNF-α there is a three fold increase of expression. As more work is done on the 
role CYP4F11 has during an inflammatory response this information will be of use 
in determining the link between inflammation, CYP4F11 and cell metabolism 
function. 
Conclusion
# This research project has many parts that when placed together create a 
picture of how CYP4Fs are expressed and how inflammatory mediators especially 
TNF-α, play an important role in the regulation of this family of enzymes. We 
believe that the expression of CYP4F2 and CYP4F3B at high levels across a 
diverse array  of tissues helps to create homeostasis in the body by regulating LTB4 
levels and 20-HETE levels in their specific organs. As inflammatory response 
signals infiltrate the tissue they are able to regulate the expression of these 
enzymes so that the normal host defense mechanism can take place. In the 
example of the liver presented in Chapter 2, inflammation increased CYP4F11 
expression and the presence of CYP4F3B, but at the same time it caused a 
decrease in CYP4F2 expression. These regulatory functions are necessary  both 
for the normal host defense process and then the subsequent return to normal 
functional state. The reduction in CYP4F2 helps to keep LTB4 present at the site of 
infection or injury so that neutrophils can be recruited to area. The increase in 
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CYP4F11 and CYP4F3B helps to increase the levels of 20-HETE which has also 
been associated with the presence of inflammation [107]. As all of this is taking 
place during the pro-inflammatory state, the switch to the anti-inflammatory stage 
leads to a time dependent increase in CYP4F2, which provides greater LTB4 
metabolism while also decreasing the presence of CYP4F3B and CYP4F11 
expression. This hypothesis of regulatory controls still needs further elaboration, 
but the work done in this current research project has added new pieces to the 
puzzle.
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